A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples